Vanguard Asset Management
VRDN icon

Vanguard Asset Management’s Viridian Therapeutics VRDN Stock Holding History

Vanguard Asset Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.13M Hold
54,915
– – ﹤0.01% 1804
2026
Q2 		$1.01M Buy
54,915
+11,344
+26% +$183K ﹤0.01% 1871
2026
Q1 		$852K Buy
+43,571
New +$1.29M ﹤0.01% 1863

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Vanguard Asset Management's VRDN Position: Q3 2026 in Review

Vanguard Asset Management held its Viridian Therapeutics (VRDN) position steady in Q3 2026 at 54,915 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Vanguard Asset Management first reported a position in VRDN in Q1 2026 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Vanguard Asset Management held 54,915 shares of Viridian Therapeutics worth $1.13M as of Q3 2026.
  • Vanguard Asset Management left its Viridian Therapeutics share count unchanged in Q3 2026.
  • Viridian Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q3 2026, its #1804 holding.
  • Vanguard Asset Management first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 154 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.